Announcement PDF 1 ASX RELEASE 13 July 2026 Cleansing Notice - Issue of Convertible Notes This cleansing notice (“Cleansing Notice”) is given by Paradigm Biopharmaceuticals Ltd (ASX:PAR) (“Paradigm” or “the Company”), under section 708A(12C)(e) of the Corporations Act 2001 (Cth) (“Corporations Act”) as amended by ASIC Corporations (Sale Offers: Securities Issued on Conversion of Convertible Notes) Instrument 2016/82. The Company hereby confirms that: (a) the convertible notes described below have been issued without disclosure to an investor under Part 6D.2 of the Corporations Act; and (b) this Cleansing Notice has been given in accordance with section 708A(12C)(e) of the Corporations Act. The issue of this Cleansing Notice enables the fully paid ordinary shares in the capital of the Company (“Shares”) issued on the conversion of the convertible notes issued by the Company on the terms described below, to be on-sold to retail investors without further disclosure. This Cleansing Notice is important and should be read in its entirety. 1. Background As announced on 1 July 2025, the Company has entered into a convertible securities and share placement agreement (“Convertible Securities Agreement”) and secured commitments for up to US$27,000,000 through the issuance of convertible notes (“Convertible Notes”) to Obsidian Global GP LLC (“Obsidian”) comprising an initial drawdown of US$7,000,000 plus any subsequent drawdowns as agreed between the Company and Obsidian. On 7 July 2025 the first drawdown of US$7,000,000 was provided to the Company in exchange for the issue of 7,000,000 Convertible Notes (each with a face value of US$1.09) (“Initial Notes”). In addition, the Company issued a total of 8,000,000 Shares to Obsidian in consideration for entering into the Convertible Securities Agreement (“Placement Shares”). The Placement Shares were issued on 2 July 2025, and are intended to be used to offset any future Shares issued to Obsidian at its discretion. During the term of the Convertible Securities Agreement, Obsidian may elect to use the Placement Shares to offset the Company's obligation to issue Shares under the Convertible Securities Agreement. Where there is a continuing event of default under the Convertible Securities Agreement, Obsidian may reduce the number of Placement Shares by paying the Company an amount equal to the amount of Placement Shares to be reduced multiplied by 94% of the average of the lowest five daily volume weighted average prices ("VWAP") in the 20 trading days prior to the payment notice. At maturity, any unpaid Placement Shares will either be sold on-market with the net sales proceeds remitted to the Company, or transferred to a nominee of the Company for no consideration. 2 The Initial Notes and the Placement Shares were issued utilising the Company’s available placement capacity under ASX Listing Rule 7.1. Subject to mutual agreement and the satisfaction of other standard conditions precedent, the Company may drawdown up to an additional US$20,000,000 in exchange for the issue of up to an additional 20,000,000 convertible notes (each with a face value of US$1.09) (“Subsequent Notes”). In accordance with the Convertible Securities Agreement, and as announced on 17 November 2025, 18 February 2026 and 13 July 2026, respectively, the Company has now completed further drawdowns under the Convertible Securities Agreement as follows: (a) US$5,000,000 in exchange for the issue of 5,000,000 Subsequent Notes (“November 2025 Notes”); and (b) US$5,000,000 in exchange for the issue of 5,000,000 Subsequent Notes (“February 2026 Notes”) (c) US$3,000,000 in exchange for the issue of 3,000,000 Subsequent Notes ("July 2026 Notes"). For further information in relation to the Convertible Securities Agreement, please refer to the Company’s announcements dated 1 July 2025, 17 November 2025, 18 February 2026 and 13 July 2026 and Schedule 1 below. A broad summary of the rights, privileges and restrictions attaching to the July 2026 Notes is set out in Schedule 1 of this Cleansing Notice. The summary is not exhaustive and does not constitute a definite statement of the rights and liabilities of the holder of the July 2026 Notes (“Noteholder”). This Cleansing Notice is in respect of the July 2026 Notes only. Any additional issues of Subsequent Notes (if any) will be cleansed under separate cleansing notices or cleansing prospectuses. 2. Contents of this Cleansing Notice This Cleansing Notice sets out the following: (a) in relation to the July 2026 Notes: (i) the effect of the issue on the Company; (ii) a summary of the rights and liabilities attaching to the July 2026 Notes; and (iii) a summary of the rights and liabilities attaching to the Shares that will be issued on the conversion of the July 2026 Notes; and (b) any information that: (i) has been excluded from continuous disclosure notices in accordance with the ASX Listing Rules; and 3 (ii) is information that investors and their professional advisors would reasonably require for the purpose of making an informed assessment of: (A) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; and (B) the rights and liabilities attaching to the Shares; and (c) other information relating to the Company’s status as a disclosing entity. 3. The effect of the issue on the Company 3.1 Effect of the issue on the Company The principal effect of the issue of the July 2026 Notes on the Company is as follows: (a) increases the Company’s cash reserves by US$3,000,000 (before costs associated with the July 2026 Notes); (b) increases the number of unquoted convertible notes on issue from 5,447,185 to 8,447,185; (c) the Company incurring a secured liability for the aggregate face value of the July 2026 Notes (being US$3,270,000); and (d) if the July 2026 Notes are converted, either wholly or in part to Shares, increase the number of Shares on issue as a consequence of the issue of Shares on such conversion. 3.2 Pro-forma Consolidated Statement of Financial Position To illustrate the effect of the issue of the July 2026 Notes on the Company, a pro-forma Consolidated Statement of Financial Position (“Pro-forma Accounts”) which is set out below has been prepared based on the financial position in the Company’s 31 December audited half year report. The Pro-forma Accounts shows the effect of the issue of the July 2026 Notes as if they had been issued on 31 December 2025, and no other transactions, have occurred. In particular the Pro‐Forma Accounts do not show the effect of the issue of any subsequent issue of Convertible Notes. The accounting policies adopted in the preparation of the Pro-forma Accounts are the same as those used in the preparation of the 31 December 2025 audited accounts. The historical and Pro-forma Accounts are presented in an abbreviated form, insofar as they do not include all of the disclosures required by Australian Accounting Standards applicable to annual financial statements. The Pro-forma Accounts have not been subject to independent audit or review. The Pro-forma Accounts have been prepared to provide investors with information on the assets and liabilities of the Company and pro-forma assets and liabilities on the basis that the issue of the July 2026 Notes were issued on 31 December 2025. The Company advises that the Pro-forma Accounts is not the current financial position of 4 the Company as at the date of this Cleansing Notice, and that the information is provided for illustrative purposes only. The Pro-forma Accounts show the impact that the issue of the July Notes and associated securities would have had on the Company’s financial position as at 31 December 2025, if these securities were issued on that date, taking into account funds of US$3,000,000 received (before costs) on the issue of the July 2026 Notes to Obsidian and the conversion of the July 2026 Notes to shares. Consolidated Statement of Financial Position Audited 31-Dec-25 ($) Effect of Issue of Convertible Notes ($) Costs of Issue of Convertible Notes ($) Pro-forma 31-Dec-25 ($) Assets Current Assets Cash and Cash Equivalents 14,663,339 4,326,752 (15,000)1 18,975,091 Trade and Other Receivables 6,311,152 6,311,152 Prepaid expenses 622,154 622,154 Financial assets held at amortised cost 71,832 71,832 Total Current Assets 21,668,477 25,980,229 Non-Current Assets Intangible assets 905,854 905,854 Plant and equipment 7,497 7,497 Right-of-use assets 570,949 570,949 Total Non-Current Assets 1,484,300 1,484,300 Total Assets 23,152,777 27,464,529 Liabilities Current Liabilities Trade and Other Payables 4,436,993 4,436,993 Employee benefits 580,473 580,473 Lease liabilities 137,948 137,948 Financial Derivative Liability 2,644,000 2,644,000 Financial Liability 8,803,707 4,715,648 13,519,355 Total Current Liabilities 16,603,121 21,318,769 Non-Current Liabilities Employee benefits 115,154 115,154 Lease liabilities 436,809 436,809 5 Consolidated Statement of Financial Position Audited 31-Dec-25 ($) Effect of Issue of Convertible Notes ($) Costs of Issue of Convertible Notes ($) Pro-forma 31-Dec-25 ($) Total Non-Current Liabilities 551,963 551,963 Total Liabilities 17,155,084 21,870,732 Net Assets 5,997,693 (388,896)2 (15,000) 5,593,797 Equity Issued Capital 260,874,596 260,874,596 Share based payments reserve 4,973,179 4,973,179 Reserves (1,206,599) (1,206,599) Accumulated Losses (258,643,483) (388,896) (15,000) (259,047,379) Total Equity 5,997,693 (388,896) (15,000) 5,593,797 Notes: 1. Reimbursement of legal fees incurred by Obsidian, legal fees incurred by PAR (estimate), ASX subsequent listing fees 2. Adjustment for face value of Convertible Notes 3.3 Potential effect on capital structure (a) As at the date of this Cleansing Notice, the total number of issued Shares is 584,843,595 Shares. (b) The capital structure of the Company will be affected by the conversion of the July 2026 Notes by the Noteholder. (c) Subject to limits on the conversion/redemption under the Convertible Securities Agreement, the July 2026 Notes: (i) prior to the date that is 24 months from the issue of the July 2026 Notes (“Maturity Date”), can be converted into Shares in whole or in part at the Noteholder’s election by issuing a conversion notice (Conversion Notice) at: (A) any time at the fixed conversion price of 150% of the 5-day VWAP for the 5 actual trading days immediately prior to the purchase date (being, AUD$0.2577) (“Fixed Conversion Price”); (B) after the day which is 30 days after the execution date, being 1 July 2025, and where the 10-day VWAP for the 10 trading days immediately prior to the relevant Conversion Notice date is less than the Fixed Conversion Price, at the "Variable Conversion Price", being the lesser of: (I) 94% of the average of the lowest 5 daily VWAPs during the 20 actual trading days prior to the Conversion Notice date rounded down to the lowest A$0.01; and 6 (II) the Fixed Conversion Price; or (C) in the event of an unremedied event of default and the Noteholder issuing the Company a conversion notice, the lesser of: (I) 85% of the lowest daily VWAP during the 10 trading days prior to the date of the Conversion Notice date; and (II) the Fixed Conversion Price. (ii) can be redeemed prior to the Maturity Date at the request of the Company; (iii) where the Company raises funds in aggregate of less than US$20,000,000 from any source (other than from the Investor), Obsidian may require the Company to apply up to 10% of the proceeds of the funds raised (from the first US$20,000,000 raised) to redeem the July 2026 Notes; (iv) where the Company raises funds in aggregate of more than US$20,000,000 from any source (other than from the Investor), Obsidian may require the Company to apply up to 15% of the proceeds of the funds raised (from the funds raised in excess of US$20,000,000) to redeem the July 2026 Notes; or (v) must be redeemed by the Company on the Maturity Date. (d) The effect on the capital structure of the Company upon the issue and conversion of the July 2026 Notes is as follows: Upon issue: Convertible Notes Number Convertible notes on issue at the date of this Cleansing Notice, before the issue of the July 2026 Notes 5,447,185 July 2026 Notes issued under the Convertible Securities Agreement 3,000,000 Total convertible notes on issue following issue of the July 2026 Notes 8,447,185 Upon conversion (assuming conversion occurs using the Fixed Conversion Price): Shares Number Shares on issue as at the date of this Cleansing Notice 584,843,595 Maximum number that may be issued on conversion of July 2026 Notes1 18,272,410 Total Shares on issue following conversion of July 2026 Notes 603,116,005 Notes: 1. Based on an USD:AUD exchange rate of $1.44. 7 Upon conversion (assuming conversion occurs using the Variable Conversion Price): Shares Number Shares on issue as at the date of this Cleansing Notice 584,843,595 Maximum number that may be issued on conversion of July Notes1,2 29,430,000 Total Shares on issue following conversion of July Notes 614,273,595 Notes: 1. Based on an USD:AUD exchange rate of $1.44. 2. Assumes a variable conversion price of $0.16 being 94% of the average of the lowest 5 daily volume weighted average prices during the 20 actual trading days before 13 July 2026. Other securities currently on issue: The Company currently has the following other securities on issue: (i) 3,000,000 unquoted options exercisable at $0.65 on or before 30 June 2027; (ii) 151,293 unquoted options exercisable at $1.00 on or before 11 February 2028; (iii) 117,069,101 quoted options exercisable at $0.2375 on or before 1 December 2026 or 20 business days following release of interim analysis outcome; and (iv) 11,127,100 performance rights. There will be no resulting change to the number of options or performance rights on issue upon the issue or conversion of the July 2026 Notes. 4. Rights and liabilities attaching to Shares issued on conversion of the July 2026 Notes The Shares issued to the Noteholder on the conversion of the July 2026 Notes under the Convertible Securities Agreement will rank equally in all respects with all of the Company’s existing Shares. Under the Convertible Securities Agreement, the Company is required to apply to ASX for quotation of the Shares issued on conversion of any July 2026 Notes. Full details of the rights and liabilities attaching to Shares are set out in the Company’s constitution, a copy of which can be inspected free of charge, at the Company’s registered office during normal business hours. The following is a broad summary of the rights, privileges and restrictions attaching to all Shares. This summary is not exhaustive and does not constitute a definitive statement of the rights and liabilities of Shareholders. (a) General meetings Shareholders are entitled to be present in person, or by proxy, attorney or representative to attend and vote at general meetings of the Company. The 8 Company’s constitution permits the use of technology at general meetings of shareholders (including wholly virtual meetings) to the extent permitted under the Corporations Act, ASX Listing Rules and applicable law. Shareholders may requisition meetings in accordance with section 249D of the Corporations Act and the constitution of the Company (Constitution). (b) Voting rights Subject to any rights or restrictions for the time being attached to any class or classes of shares, at general meetings of shareholders or classes of shareholders: (i) each Shareholder entitled to vote may vote in person or by proxy, attorney or representative; (ii) on a show of hands, every person present who is a Shareholder or a proxy, attorney or representative of a Shareholder has one vote; and (iii) on a poll, every person present who is a Shareholder or a proxy, attorney or representative of a Shareholder shall, in respect of each fully paid Share held by him, or in respect of which he is appointed a proxy, attorney or representative, have one vote for each Share held, but in respect of partly paid shares shall have such number of votes as bears the same proportion to the total of such Shares registered in the Shareholder’s name as the amount paid (not credited) bears to the total amounts paid and payable (excluding amounts credited). (c) Dividend rights Subject to the rights of any preference Shareholders and to the rights of the holders of any shares created or raised under any special arrangement as to dividend, the directors of the Company (Directors) may from time to time declare a dividend to be paid to the Shareholders entitled to the dividend which shall be payable on all Shares according to the proportion that the amount paid (not credited) is of the total amounts paid and payable (excluding amounts credited) in respect of such Shares. The Directors may from time to time pay to the Shareholders any interim dividends as they may determine. No dividend shall carry interest as against the Company. The Directors may set aside out of the profits of the Company any amounts that they may determine as reserves, to be applied at the discretion of the Directors, for any purpose for which the profits of the Company may be properly applied. Subject to the ASX Listing Rules and the Corporations Act, the Company may, by resolution of the Directors, implement a dividend reinvestment plan on such terms and conditions as the Directors think fit and which provides for any dividend which the Directors may declare from time to time payable on Shares which are participating Shares in the dividend reinvestment plan, less any amount which the Company shall either pursuant to the Constitution or 9 any law be entitled or obliged to retain, be applied by the Company to the payment of the subscription price of Shares. (d) Winding-up If the Company is wound up, the liquidator may, with the authority of a special resolution, divide among the Shareholders in kind the whole or any part of the property of the Company, and may for that purpose set such value as he considers fair upon any property to be so divided, and may determine how the division is to be carried out as between the Shareholders or different classes of Shareholders. The liquidator may, with the authority of a special resolution, vest the whole or any part of any such property in trustees upon such trusts for the benefit of the contributories as the liquidator thinks fit, but so that no Shareholder is compelled to accept any shares or other securities in respect of which there is any liability. (e) Shareholder liability As the Shares issued will be fully paid shares, they will not be subject to any calls for money by the Directors and will therefore not become liable for forfeiture. (f) Transfer of shares Generally, shares in the Company are freely transferable, subject to formal requirements, the registration of the transfer not resulting in a contravention of or failure to observe the provisions of a law of Australia and the transfer not being in breach of the Corporations Act and the ASX Listing Rules. (g) Future increase in capital The issue of any new Shares is under the control of the Directors of the Company. Subject to restrictions on the issue or grant of securities contained in the ASX Listing Rules, the Constitution and the Corporations Act (and without affecting any special right previously conferred on the holder of an existing share or class of shares), the Directors may issue Shares as they shall, in their absolute discretion, determine. (h) Variation of rights Under section 246B of the Corporations Act, the Company may, with the sanction of a special resolution passed at a meeting of Shareholders vary or abrogate the rights attaching to Shares. If at any time the share capital is divided into different classes of shares, the rights attached to any class (unless otherwise provided by the terms of issue of the shares of that class), whether or not the Company is being wound up, may be varied or abrogated with the consent in writing of the holders of three quarters of the issued shares of that class, or if authorised by a special resolution passed at a separate meeting of the holders of the shares of that class. 10 (i) Alteration of constitution In accordance with the Corporations Act, the Constitution can only be amended by a special resolution passed by at least three quarters of Shareholders present and voting at the general meeting. In addition, at least 28 days written notice specifying the intention to propose the resolution as a special resolution must be given. 5. Compliance with disclosure obligations The Company is a “disclosing entity” under the Corporations Act and, as such, is subject to regular reporting and disclosure obligations under both the Corporations Act and the ASX Listing Rules. These obligations require the Company to notify ASX of information about specific events and matters as they arise. In particular, the Company is obliged to continuously disclose to the market immediately any information which a reasonable person would expect to have a material effect on the price or the value of the Shares. The Company is also required to prepare and lodge with ASIC yearly and half-yearly financial statements accompanied by a directors’ statement and report, and an audit report or review. Copies of documents lodged with ASIC in relation to the Company may be obtained from, or inspected at, an ASIC office. The Company will provide a copy of each of the following documents, free of charge, to any person on request: (a) the annual financial report most recently lodged by the Company with ASIC, being the financial report of the Company for the year ended 30 June 2025; (b) any half-year financial report lodged by the Company with ASIC after the lodgement of the annual financial report referred to in paragraph (a) and before the lodgement of this Cleansing Notice with ASX, being the annual financial report of the Company for the half year ended 31 December 2025; and (c) any continuous disclosure notices given by the Company to ASX after the lodgement of the annual financial report referred to in paragraph (a) and before the lodgement of this Cleansing Notice with ASX. A list of the continuous disclosure notices given by the Company to ASX after lodgement of the annual financial report referred to in paragraph (a) above and before the date of lodgement of this Cleansing Notice with ASX is set out in the table below. Date Description of Announcement 13 July 2026 Notification regarding unquoted securities - PAR 13 July 2026 Drawdown of Tranche 4 under the Convertible Note Facility 1 July 2026 Change of Director's Interest Notice 29 June 2026 Notification of cessation of securities - PAR 29 June 2026 Notification of cessation of securities - PAR 18 June 2026 Change of Director's Interest Notice 11 Date Description of Announcement 18 June 2026 Change of Director's Interest Notice 18 June 2026 Application for quotation of securities - PAR 17 June 2026 Listing of Options - Top 20 Holders and Distribution Reports 17 June 2026 Application for quotation of securities - PAR 15 June 2026 PAR Completes Enrolment in Pivotal Phase 3 11 June 2026 Options Prospectus 11 June 2026 Results of Meeting 5 June 2026 Change of Director's Interest Notice 5 June 2026 Change of Director's Interest Notice 4 June 2026 Ceasing to be a substantial holder 3 June 2026 Notification of cessation of securities - PAR 2 June 2026 Application for quotation of securities - PAR 2 June 2026 Application for quotation of securities - PAR 1 June 2026 Update - Proposed issue of securities - PAR 1 June 2026 Results of Share Purchase Plan 12 May 2026 Notice of General Meeting/Proxy Form 5 May 2026 Becoming a substantial holder 1 May 2026 Cleansing Notice 1 May 2026 Application for quotation of securities - PAR 30 April 2026 Variation to Convertible Securities Agreement 30 April 2026 Share Purchase Plan - Offer Booklet 30 April 2026 DSMB 20% Review Supports Phase 3, Moldova Activated 29 April 2026 OARSI Theatre Presentation Showcases iPPS Biomarker Data 27 April 2026 March 2026 Quarterly Activities Report & Appendix 4C 27 April 2026 Proposed issue of securities - PAR 27 April 2026 Proposed issue of securities - PAR 27 April 2026 Upsized $14M Placement Extends Runway Post IA 23 April 2026 Trading Halt 8 April 2026 Application for quotation of securities - PAR 2 April 2026 Paradigm Announces OA Research Collaboration in UK 31 March 2026 Paradigm Achieves 50% Patient Dosing in Phase 3 20 March 2026 Hong Kong Site Activated for Phase 3 OA Study 16 March 2026 Application for quotation of securities - PAR 27 February 2026 Appendix 4D and Half Year Report 23 February 2026 Change of Director's Interest Notice 12 Date Description of Announcement 23 February 2026 Change of Director's Interest Notice 19 February 2026 Notification regarding unquoted securities - PAR 18 February 2026 Notice under Section 708A 18 February 2026 Notification regarding unquoted securities - PAR 18 February 2026 Drawdown of Tranche 3 under the Convertible Note Facility 17 February 2026 Notification regarding unquoted securities - PAR 17 February 2026 Application for quotation of securities - PAR 16 February 2026 Update on PAROA Exercise and Unmarketable Parcel Facility 16 February 2026 Application for quotation of securities – PAR 11 February 2026 Published Canine Study Strengthens iPPS Phase 3 Rationale 10 February 2026 Notification of cessation of securities - PAR 9 February 2026 Oral OA Animal Therapy Progresses via AVet Deal 4 February 2026 Change of Director's Interest Notice 3 February 2026 Application for quotation of securities - PAR 30 January 2026 Application for quotation of securities - PAR 30 January 2026 December 2025 Quarterly Activities Report & Appendix 4C 28 January 2026 iPPS Phase 2 Biomarker Results Published in Leading Journal 27 January 2026 Application for quotation of securities - PAR 16 January 2026 Application for quotation of securities - PAR 9 January 2026 Upcoming Expiry of PAROA Listed Options 23 December 2025 Phase 3 Knee OA Trial Recruitment Update 19 November 2025 Results of Meeting 19 November 2025 2025 AGM Chair Address and Presentation 17 November 2025 Notice under Section 708A 17 November 2025 Notification regarding unquoted securities - PAR 17 November 2025 Drawdown of Tranche 2 under the Convertible Note Facility 12 November 2025 Ceasing to be a substantial holder 12 November 2025 PAR Engages NBCD to Expand P3 Global Footprint 7 November 2025 Notification regarding unquoted securities - PAR 30 October 2025 Application for quotation of securities - PAR 30 October 2025 September 2025 Quarterly Activities Report & Appendix 4C 20 October 2025 Notice of Annual General Meeting/Proxy Form 8 October 2025 Application for quotation of securities - PAR 30 September 2025 Phase 3 Knee OA Trial Recruiting and Dosing in AUS & US 23 September 2025 Results of Meeting 13 Date Description of Announcement 22 September 2025 Date of AGM and closing date for director nominations 11 September 2025 Unmarketable Parcel Sale Facility 9 September 2025 Application for quotation of securities - PAR 9 September 2025 Evans and Partners Healthcare Conference Presentation 29 August 2025 Appendix 4G and Corporate Governance Statement 29 August 2025 Appendix 4E and 2025 Annual Report 6. Information excluded from continuous disclosure notices As at the date of this Cleansing Notice, the Company advises that it has fully complied with its disclosure obligations under the ASX Listing Rules and the Corporations Act, and, in particular, there is no information which the Company has excluded from any of its continuous disclosure notices given in accordance with the ASX Listing Rules and the Corporations Act as at the date of this Cleansing Notice which it would be reasonable for investors and their professional advisors to require for the purpose of making an informed assessment of: (a) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; and (b) the rights and liabilities attaching to the July 2026 Notes and the Shares. Authorised on behalf of the Board of Directors. Paul Rennie Managing Director Paradigm Biopharmaceuticals Ltd. Important Notice Statements in this announcement are made only as of the date of this announcement unless otherwise stated and the information in this announcement remains subject to change without notice. To the maximum extent permitted by law, neither Paradigm nor any of its affiliates, related bodies corporate, their respective officers, directors, employees, advisors and agents or any other person accepts any liability as to or in relation to the accuracy or completeness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this announcement or any omission from this announcement or of any other written or oral information or opinions provided now or in the future to any person. -Ends- 14 About Paradigm Biopharmaceuticals Ltd. Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of iPPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2). Forward Looking Statements This Company announcement contains forward-looking statements, including statements regarding anticipated commencement dates or completions dates of preclinical or clinical trials, regulatory developments and regulatory approval. These forward-looking statements are not guarantees or predictions of future performance, and inv